Lykos PBC is a mental health technology company that specializes in creating solutions to improve access to mental health care. The company focuses on leveraging technology to connect individuals with mental health professionals and resources, aiming to make mental health care more accessible and effective.

At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. 

Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com. 

Lykos Therapeutics (formerly MAPS PBC)

We are proud to announce the FDA acceptance and priority review of our new drug application (NDA) filing for our investigational therapy for post-traumatic stress disorder #PTSD in adults. 

Learn more about this exciting milestone below.  

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) announced that PLOS has published the first study comparing the effects of investigational MDMA-assisted therapy and therapy with placebo on emotional coping skills and self-experience in adults with severe PTSD. The study explored how changes in self-experience impacted PTSD scores in the Company’s Phase 3, randomized, double-blind placebo-controlled study (MAPP1), previously published in Nature Portfolio. 

Results showed that compared to therapy with placebo, MDMA-assisted therapy had a statistically significant greater improvement in all self-experience measures such as self-compassion and being in touch with oneself. 

MAPS PBC raised more than $100 million including conversion of previously issued convertible notes with the closing of our oversubscribed Series A financing. Learn more about this significant milestone:


Same commitment, new name! MAPS PBC is now Lykos Therapeutics. Selecting the name Lykos – wolf in Greek – was a purposeful decision made to represent bravery, courage, loyalty and intelligence, all things we embody at our company. 

MAPS PBC announced today that the American Medical Association CPT III codes for psychedelic-assisted therapy\ies, first announced in July 2023, are now in effect. These temporary codes are assigned to emerging technologies to facilitate reimbursement and support access to psychedelic therapies in the United States, if such therapies receive regulatory approval by the #FDA. 
 
The new CPT codes will provide healthcare providers with a means to seek coverage and reimbursement for delivering psychedelic-assisted therapy if approved by the FDA.


COM:LYKOSPBC

Lykos PBC

Analysis Not Available